<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="6117">
  <stage>Registered</stage>
  <submitdate>21/09/2016</submitdate>
  <approvaldate>21/09/2016</approvaldate>
  <nctid>NCT02924883</nctid>
  <trial_identification>
    <studytitle>A Study to Evaluate the Efficacy and Safety of Trastuzumab Emtansine in Combination With Atezolizumab or Atezolizumab-Placebo in Participants With Human Epidermal Growth Factor-2 (HER2) Positive Locally Advanced or Metastatic Breast Cancer (BC) Who Received Prior Trastuzumab and Taxane Based Therapy</studytitle>
    <scientifictitle>A Randomized, Multicenter, Double-Blind, Placebo-Controlled Phase II Study of the Efficacy and Safety of Trastuzumab Emtansine in Combination With Atezolizumab or Atezolizumab-Placebo in Patients With HER2-Positive Locally Advanced or Metastatic Breast Cancer Who Have Received Prior Trastuzumab and Taxane Based Therapy</scientifictitle>
    <utrn />
    <trialacronym>KATE2</trialacronym>
    <secondaryid>2015-004189-27</secondaryid>
    <secondaryid>WO30085</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Metastatic Breast Cancer</healthcondition>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Breast</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - Atezolizumab
Treatment: drugs - Trastuzumab emtansine
Other interventions - Placebo

Experimental: Trastuzumab Emtansine + Atezolizumab/Placebo - Atezolizumab 1200 milligrams (mg) intravenous (IV) infusion or matching Placebo followed by trastuzumab emtansine 3.6 milligrams per kilogram (mg/kg) IV infusion on Day 1 Cycle 1 and thereafter on Day 1 of each 21-day cycle until disease progression, unmanageable toxicity, or study termination by the Sponsor (approximately 29 months)

Active Comparator: Trastuzumab Emtansine + Placebo - Placebo matched to atezolizumab followed by trastuzumab emtansine 3.6 mg/kg IV infusion on Day 1 Cycle 1 and thereafter on Day 1 of each 21-day cycle until disease progression, unmanageable toxicity, or study termination by the sponsor (approximately 29 months)


Treatment: drugs: Atezolizumab
Atezolizumab 1200 mg IV infusion

Treatment: drugs: Trastuzumab emtansine
Trastuzumab emtansine 3.6 mg/kg IV infusion

Other interventions: Placebo
Placebo matched to atezolizumab

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
    <interventioncode>Other interventions interventions</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Progression-Free Survival (PFS) as Determined by Investigator's Tumor Assessment Using Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 (v1.1)</outcome>
      <timepoint>Baseline until disease progression or death (approximately 29 months)</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Percentage of Participants with Adverse Events</outcome>
      <timepoint>Baseline up to end of study (approximately 29 months)</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Overall Survival (OS)</outcome>
      <timepoint>Baseline until death or end of study (approximately 29 months)</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Percentage of Participants With Objective Response (OR) as Determined by Investigator's Tumor Assessment Using RECIST v1.1</outcome>
      <timepoint>Baseline until disease progression or death (approximately 29 months)</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Duration of OR as Determined by Investigator's Tumor Assessment Using RECIST v1.1</outcome>
      <timepoint>Baseline until disease progression or death (approximately 29 months)</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Maximum Serum Concentration (Cmax) of Trastuzumab Emtansine</outcome>
      <timepoint>Pre-infusion (0 hour [h]), 30 minutes (min) after end of infusion (EOI) (over 90 min) on Day 1 Cycles 1 and 4; pre-infusion (0 h) on Day 1 Cycle 2 (each cycle = 21 days); at any time during study treatment/early discontinuation visit (approx. 29 months)</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Serum Concentration of Total Trastuzumab</outcome>
      <timepoint>Pre-infusion (0 h), 30 min after EOI (over 90 min) on Day 1 Cycles 1 and 4; pre-infusion (0 h) on Day 1 Cycle 2 (each cycle = 21 days)</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Maximum Plasma Concentration of Deacetyl Mercapto 1-Oxopropyl Maytansine</outcome>
      <timepoint>Pre-infusion (0 h) on Day 1 Cycle 1 and 30 min after EOI (over 90 min) on Day 1 Cycles 1 and 4 (each cycle = 21 days)</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Cmax of Atezolizumab</outcome>
      <timepoint>Pre-infusion (0 h), 30 min after EOI (over 60 min) on Day 1 Cycles 1 and 4; pre-infusion (0 h) on Day 1 Cycles 2, 3, 8, and every 8 cycles thereafter (each cycle=21 days) up to 120 days after treatment completion/early discontinuation (approx. 29 months)</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Percentage of Participants With Anti-therapeutic Antibodies (ATAs) to Atezolizumab</outcome>
      <timepoint>Pre-infusion (0 h) on Day 1 Cycles 1, 2, 3, 4, 8, and every 8 cycles thereafter (each cycle = 21 days) up to 120 days after treatment completion or early discontinuation (approximately 29 months)</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Percentage of Participants With ATAs to Trastuzumab Emtansine</outcome>
      <timepoint>Pre-infusion (0 h) on Day 1 Cycles 1 and 4 (each cycle = 21 days); and at any time during study treatment/early discontinuation visit (approximately 29 months)</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Archival tumor samples must be obtained from primary and/or metastatic sites

          -  Able to submit tumor tissue that is evaluable for programmed death- ligand 1 (PD-L1)
             expression

          -  HER-2 positive BC as defined by an immunohistochemistry score of 3 or gene amplified
             by in-situ hybridization as defined by a ratio of greater than or equal to (&gt;=) 2.0
             for the number of HER2 gene copies to the number of chromosome 17 copies

          -  Histologically or cytologically confirmed invasive BC: incurable, unresectable,
             locally advanced BC previously treated with multimodality therapy or metastatic BC

          -  Prior treatment for BC in the: adjuvant; unresectable locally advanced; or metastatic
             settings; which must include both, a taxane and trastuzumab (alone or in combination
             with another agent)

          -  Progression must have occurred during or after most recent treatment for locally
             advanced/metastatic BC or within 6 months after completing adjuvant therapy

          -  Participants must have measurable disease that is evaluable as per RECIST v1.1

          -  Eastern Cooperative Oncology Group Performance Status of 0 or 1

          -  Negative serum pregnancy test within 7 days of enrollment for pre-menopausal women and
             for women less than 12 months after the onset of menopause

          -  Use of highly effective method of contraception as defined by the protocol</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Prior treatment with trastuzumab emtansine, cluster of differentiation 137 agonists,
             anti-programmed death-1, or anti-PD-L1 therapeutic antibody or pathway-targeting
             agents

          -  Receipt of any anti-cancer drug/biologic or investigational treatment within 21 days
             prior to Cycle 1 Day 1 except hormone therapy, which can be given up to 7 days prior
             to Cycle 1 Day 1; recovery of treatment related toxicity consistent with other
             eligibility criteria

          -  Radiation therapy within 2 weeks prior to Cycle 1, Day 1

          -  History of exposure to the cumulative doses of anthracyclines

          -  History of other malignancy within the previous 5 years, except for appropriately
             treated carcinoma in situ of the cervix, non-melanoma skin carcinoma, Stage I uterine
             cancer, or participants who have undergone potentially curative therapy with no
             evidence of disease and are deemed by the treating physician to be at low risk for
             recurrence

          -  Cardiopulmonary dysfunction, symptomatic pleural effusion, pericardial effusion, or
             ascites

          -  Participants with severe infection within 4 weeks prior to randomization, including
             but not limited to hospitalization for complications of infection, bacteremia, or
             severe pneumonia

          -  Current severe, uncontrolled systemic disease

          -  Major surgical procedure or significant traumatic injury within 28 days prior to
             randomization or anticipation of the need for major surgery during the course of study
             treatment

          -  Clinically significant history of liver disease, including cirrhosis, current alcohol
             abuse, autoimmune hepatic disorders, sclerosis cholangitis or active infection with
             human immunodeficiency virus, hepatitis B virus, or hepatitis C virus

          -  Need for current chronic corticosteroid therapy (&gt;=10 mg of prednisone per day or an
             equivalent dose of other anti-inflammatory corticosteroids)

          -  Spinal cord compression not definitively treated with surgery and/or radiation, or
             previously diagnosed and treated spinal cord compression without evidence that disease
             has been clinically stable for greater than (&gt;) 2 weeks prior to randomization

          -  Participants with known central nervous system disease

          -  Leptomeningeal disease

          -  History of autoimmune disease

          -  Prior allogeneic stem cell or solid organ transplantation

          -  Active tuberculosis

          -  Receipt of a live, attenuated vaccine within 4 weeks prior to randomization or
             anticipation that such a live, attenuated vaccine will be required during the study

          -  Treatment with systemic immunostimulatory agents within 4 weeks or five half-lives of
             the drug (whichever is shorter) prior to randomization

          -  Treatment with systemic corticosteroids or other systemic immunosuppressive
             medications within 2 weeks prior to randomization, or anticipated requirement for
             systemic immunosuppressive medications during the trial

          -  Participants who are breastfeeding, or intending to become pregnant during the study</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1>The people receiving the treatment/s</masking1>
    <masking2 />
    <masking3 />
    <masking4>The people analysing the results/data</masking4>
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate />
    <actualstartdate>26/09/2016</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize>200</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Active, not recruiting</recruitmentstatus>
    <anticipatedlastvisitdate>29/08/2019</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW,QLD,VIC,WA</recruitmentstate>
    <hospital>St George Hospital; Cancer Care Centre - Kogarah</hospital>
    <hospital>Calvary Mater Newcastle - Waratah</hospital>
    <hospital>Princess Alexandra Hospital Woolloongabba; Clinical Hematology and Medical Oncology - Woolloongabba</hospital>
    <hospital>Peninsula Oncology Centre - Frankston</hospital>
    <hospital>Peter MacCallum Cancer Center - Melbourne</hospital>
    <hospital>Sunshine Hospital - St Albans</hospital>
    <hospital>St John of God Hospital; Bendat Cancer Centre - Subiaco</hospital>
    <postcode>2217 - Kogarah</postcode>
    <postcode>2298 - Waratah</postcode>
    <postcode>4102 - Woolloongabba</postcode>
    <postcode>3199 - Frankston</postcode>
    <postcode>3000 - Melbourne</postcode>
    <postcode>3021 - St Albans</postcode>
    <postcode>6008 - Subiaco</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Arizona</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>California</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Colorado</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>District of Columbia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Florida</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Georgia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Louisiana</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Maryland</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Minnesota</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New Mexico</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New York</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Ohio</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Pennsylvania</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Tennessee</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Texas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Washington</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Alberta</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>British Columbia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Ontario</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Quebec</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Berlin</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Essen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Freiburg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Hamburg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Heidelberg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Koblenz</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Campania</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Emilia-Romagna</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Friuli-Venezia Giulia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Sicilia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Toscana</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Korea, Republic of</country>
      <state>Gyeonggi-do</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Korea, Republic of</country>
      <state>Seoul</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Barcelona</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Cordoba</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>La Coru√±a</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Madrid</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Valencia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Taiwan</country>
      <state>Changhua</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Taiwan</country>
      <state>Kaohsiung</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Taiwan</country>
      <state>Taichung</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Taiwan</country>
      <state>Tainan</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Taiwan</country>
      <state>Taipei</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Taiwan</country>
      <state>Taoyuan</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Bath</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Glasgow</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>London</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Manchester</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Nottingham</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Sheffield</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Sutton</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Swansea</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Truro</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Hoffmann-La Roche</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>This Phase II, double-blind, randomized, placebo-controlled multicenter study will
      investigate the efficacy and safety of trastuzumab emtansine in combination with atezolizumab
      or atezolizumab-placebo in participants with HER2-positive locally advanced or metastatic BC
      who have received prior trastuzumab and taxane based therapy, either alone or in combination,
      and/or who have progressed within 6 months after completing adjuvant therapy.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT02924883</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Clinical Trials</name>
      <address>Hoffmann-La Roche</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>